• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高病毒载量1b型丙型肝炎患者对聚乙二醇化干扰素α-2b加利巴韦林无应答的预测

Prediction of a null response to pegylated interferon α-2b plus ribavirin in patients with high viral load genotype 1b hepatitis C.

作者信息

Wada Yuki, Tamai Hideyuki, Kawashima Akira, Shingaki Naoki, Mori Yoshiyuki, Kawaguchi Masanori, Moribata Kosaku, Deguchi Hisanobu, Ueda Kazuki, Inoue Izumi, Maekita Takao, Iguchi Mikitaka, Kato Jun, Ichinose Masao

机构信息

Second Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.

Department of Internal Medicine, Naga Municipal Hospital, Kinokawa, Japan.

出版信息

Gut Liver. 2014 Jul;8(4):421-7. doi: 10.5009/gnl.2014.8.4.421. Epub 2014 Apr 23.

DOI:10.5009/gnl.2014.8.4.421
PMID:25071908
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4113039/
Abstract

BACKGROUND/AIMS: The present study aimed to clarify whether virological response within 2 weeks after therapy initiation can predict a null response to pegylated interferon α-2b plus ribavirin therapy in patients with high viral load genotype 1b hepatitis C.

METHODS

The participants consisted of 72 patients with high viral load genotype 1b. The dynamics of viral load within 2 weeks were measured.

RESULTS

Significant differences between null responders and nonnull responders were noted for interleukin (IL)-28B genotype, amino acid 70 substitution, α-fetoprotein, low-density lipoprotein cholesterol, hyaluronic acid, and viral response. The area under the curve (AUC) for the receiver operating characteristic curve of the hepatitis C virus (HCV) RNA level decline at 2 weeks (AUC=0.993) was the highest among the factors predicting the null response. When the cutoff value for the HCV RNA level decline at 2 weeks was set at 0.80 log, the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy in predicting a null response were 82%, 96%, 82%, 96%, and 94%, respectively. In comparison, values for the non-TT and mutant type of amino acid 70 substitution were similar to those for HCV RNA level decline at 2 weeks.

CONCLUSIONS

Virological response at 2 weeks or the combination of IL-28B and amino acid 70 substitution are accurate predictors of a null response.

摘要

背景/目的:本研究旨在明确在高病毒载量基因1b型丙型肝炎患者中,治疗开始后2周内的病毒学应答是否可预测聚乙二醇化干扰素α-2b联合利巴韦林治疗的无应答情况。

方法

研究对象为72例高病毒载量基因1b型患者。测定2周内病毒载量的动态变化。

结果

无应答者与非无应答者在白细胞介素(IL)-28B基因型、氨基酸70位点替换、甲胎蛋白、低密度脂蛋白胆固醇、透明质酸及病毒应答方面存在显著差异。丙型肝炎病毒(HCV)RNA水平在2周时下降情况的受试者工作特征曲线下面积(AUC=0.993)在预测无应答的因素中最高。当将2周时HCV RNA水平下降的截断值设定为0.80 log时,预测无应答的敏感性、特异性、阳性预测值、阴性预测值及准确性分别为82%、96%、82%、96%及94%。相比之下,非TT型及氨基酸70位点替换的突变型的值与2周时HCV RNA水平下降的值相似。

结论

2周时的病毒学应答或IL-28B与氨基酸70位点替换的联合是无应答的准确预测指标。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf12/4113039/7d1b087dc8f7/gnl-8-421f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf12/4113039/7d1b087dc8f7/gnl-8-421f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf12/4113039/7d1b087dc8f7/gnl-8-421f1.jpg

相似文献

1
Prediction of a null response to pegylated interferon α-2b plus ribavirin in patients with high viral load genotype 1b hepatitis C.高病毒载量1b型丙型肝炎患者对聚乙二醇化干扰素α-2b加利巴韦林无应答的预测
Gut Liver. 2014 Jul;8(4):421-7. doi: 10.5009/gnl.2014.8.4.421. Epub 2014 Apr 23.
2
Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b.预测日本丙型肝炎病毒 1b 型感染患者对聚乙二醇干扰素-α-2b 联合利巴韦林治疗的反应。
J Med Virol. 2011 Jun;83(6):981-8. doi: 10.1002/jmv.22028.
3
Low-dose pegylated interferon-α2a plus ribavirin therapy for elderly and/or cirrhotic patients with HCV genotype-1b and high viral load.低剂量聚乙二醇化干扰素-α2a联合利巴韦林治疗老年和/或肝硬化的丙型肝炎病毒1b型且病毒载量高的患者。
Antivir Ther. 2014;19(1):107-15. doi: 10.3851/IMP2696. Epub 2013 Oct 25.
4
Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy.HCV 基因型-4 在聚乙二醇干扰素 α 2a:利巴韦林治疗期间的病毒动力学。
J Viral Hepat. 2008 Aug;15(8):591-9. doi: 10.1111/j.1365-2893.2008.00988.x. Epub 2008 May 14.
5
Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.接受聚乙二醇干扰素α-2b和利巴韦林治疗的慢性丙型肝炎患者早期丙型肝炎病毒RNA变化
Rev Invest Clin. 2003 Mar-Apr;55(2):138-42.
6
Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.西美瑞韦联合聚乙二醇干扰素 α-2a 或 -2b 加利巴韦林治疗初治慢性丙型肝炎病毒基因 1 型感染患者(QUEST-2):一项随机、双盲、安慰剂对照的 3 期临床试验。
Lancet. 2014 Aug 2;384(9941):414-26. doi: 10.1016/S0140-6736(14)60538-9. Epub 2014 Jun 4.
7
Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients.对于慢性丙型肝炎基因1型感染的低反应成年患者,长效聚乙二醇干扰素联合利巴韦林治疗72周与标准聚乙二醇干扰素联合利巴韦林治疗48周的对比研究。
Cochrane Database Syst Rev. 2012 Sep 12;2012(9):CD008516. doi: 10.1002/14651858.CD008516.pub2.
8
Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.初治的1b型丙型肝炎病毒感染且病毒载量高的患者,大剂量干扰素诱导联合治疗与聚乙二醇干扰素加利巴韦林联合治疗的早期病毒动力学及治疗结果
J Med Virol. 2005 Jan;75(1):27-34. doi: 10.1002/jmv.20232.
9
Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b.慢性丙型肝炎无反应者的早期持续病毒学应答:聚乙二醇化干扰素α-2a与聚乙二醇化干扰素α-2b的随机开放标签研究
Drugs. 2008;68(6):791-801. doi: 10.2165/00003495-200868060-00005.
10
Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b.接受达卡他韦联合利巴韦林及聚乙二醇干扰素α-2a或α-2b治疗的丙型肝炎病毒1型感染患者的病毒学逃逸
Antivir Ther. 2014;19(5):479-90. doi: 10.3851/IMP2729. Epub 2014 Jan 22.

引用本文的文献

1
Hepatitis C viral kinetics as a determinant of stopping pegylated interferon and ribavirin in genotype 1 infection.丙型肝炎病毒动力学作为决定基因1型感染患者停用聚乙二醇干扰素和利巴韦林的因素
Gut Liver. 2014 Jul;8(4):335-6. doi: 10.5009/gnl.2014.8.4.335.

本文引用的文献

1
Guidelines for the Management of Hepatitis C Virus Infection: First edition, May 2012, The Japan Society of Hepatology.丙型肝炎病毒感染管理指南:第一版,2012年5月,日本肝脏学会
Hepatol Res. 2013 Jan;43(1):1-34. doi: 10.1111/hepr.12020.
2
Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1.既往对 HCV 基因型 1 感染者的 telaprevir、聚乙二醇干扰素和利巴韦林三联治疗无应答者对三联治疗应答的决定因素。
J Med Virol. 2012 Jul;84(7):1097-105. doi: 10.1002/jmv.23262.
3
Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response.
白细胞介素 28B 多态性是与基因型 1 慢性丙型肝炎患者的低密度脂蛋白胆固醇(LDL-C)相关的唯一常见遗传变异,决定了 LDL-C 与治疗反应之间的关系。
J Viral Hepat. 2012 May;19(5):332-40. doi: 10.1111/j.1365-2893.2011.01553.x. Epub 2012 Feb 22.
4
Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C.替拉瑞韦,一种新型蛋白酶抑制剂,用于治疗基因型 1 慢性丙型肝炎的难治性患者的疗效和安全性。
J Viral Hepat. 2012 Feb;19(2):e134-42. doi: 10.1111/j.1365-2893.2011.01528.x. Epub 2011 Nov 8.
5
Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan.替拉瑞韦联合聚乙二醇干扰素和利巴韦林治疗日本慢性 HCV 基因 1 型初治患者
J Hepatol. 2012 Jan;56(1):78-84. doi: 10.1016/j.jhep.2011.07.016. Epub 2011 Aug 7.
6
EASL Clinical Practice Guidelines: management of hepatitis C virus infection.欧洲肝脏研究学会临床实践指南:丙型肝炎病毒感染的管理
J Hepatol. 2011 Aug;55(2):245-64. doi: 10.1016/j.jhep.2011.02.023. Epub 2011 Mar 1.
7
Clinical characteristics of null responders to Peg-IFNα2b/ribavirin therapy for chronic hepatitis C.聚乙二醇干扰素α2b/利巴韦林治疗慢性丙型肝炎无应答者的临床特征
World J Hepatol. 2010 Nov 27;2(11):401-5. doi: 10.4254/wjh.v2.i11.401.
8
Histologic outcomes in hepatitis C-infected patients with varying degrees of virologic response to interferon-based treatments.慢性丙型肝炎患者在接受基于干扰素的治疗后,随着病毒学应答程度的不同,其组织学结果也有所不同。
Hepatology. 2010 Oct;52(4):1193-200. doi: 10.1002/hep.23809.
9
Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis.聚乙二醇干扰素和利巴韦林治疗对肝细胞癌的影响:晚期纤维化丙型肝炎患者的发生率和生存率。
J Hepatol. 2010 May;52(5):652-7. doi: 10.1016/j.jhep.2009.12.028. Epub 2010 Mar 4.
10
Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection.慢性丙型肝炎感染患者干扰素-λ 基因型与血清低密度脂蛋白胆固醇水平降低的关系。
Hepatology. 2010 Jun;51(6):1904-11. doi: 10.1002/hep.23592.